Serious Larry and Sergey con Whore Jinx out of USD$800 million of our money, dumb bit

[Sammyboy RSS Feed]

An honorable member of the Coffee Shop Has Just Posted the Following:

Why the fuck would Stomachsick invest USD$800 million for a minority share (which they do not disclose how much) in a health science startup company that is not publicly traded and majority owned by Google. does google really need their USD$800 million? What is their exit strategy? Sell the shares back to Google? I thought our Stomachsick money was for a rainy day fund, but playing venture capitalist is like gambling. If this was such a good deal, would not other more established venture capital funds be jumping on this?

Singapore investment fund Temasek will take a minority stake in Alphabet Inc.-backed biomedical company Verily Life Sciences as it ramps up its presence in the Bay Area.
The $800 million investment, disclosed Thursday, marks Alphabet's latest attempt to reduce the financial risk in its more experimental business units, such as Verily, previously known as Google Life Sciences (NASDAQ: GOOG)sanofi.


Temasek, meanwhile, is looking to step up its life sciences presence, even setting up an office in the past year in San Francisco. Its portfolio, with a net value of roughly $170 billion at the end of March 2016, covers a broad range of businesses, including financial services, transportation, telecommunications, real estate and energy.
Locally, its investments have included home-sharing company Airbnb, biofuels developer Amyris Inc., cardiac test maker CardioDx Inc. and online language education company TutorGroup.
Temasek will pay out the majority of its Verily investment "in the coming days," it said Thursday, with remainder being doled out in the second half of this year.
But the deal with Verily, which moved last year to new offices in South San Francisco, is about more than hard cash. The collaboration also opens the door for Verily's emerging but experimental products to be developed and marketed outside the United States, including China, where nearly a quarter of Temasek's investments.


"With a substantial network and insights into the economies in Asia, Temasek will provide valuable guidance as we look to ex-U.S. markets with our development partners," Verily CEO Andrew Conrad said in a prepared statement.
Verily's interests are broad, including drugs, medical devices such as its Liftware to steady Parkinson's disease patients' spoons and surgical robots in its Verb Surgical unit.
Around this time last year, Verily partnered with Johnson & Johnson (NYSE: JNJ) to create Verb. A few months later, it announced a $715 million joint venture with GlaxoSmithKline plc (NYSE: GSK) to create a bioelectronics medicine company Galvani Bioelectronics, and in September it created a $500 million joint venture with Sanofi (NYSE: SNY), called Onduo, that focuses on diabetes maintenance.

The deals — and Thursday’s investment from Temasek — helps describe the scope of Verily’s ambitions in healthcare research.




Click here to view the whole thread at www.sammyboy.com.